News for Cynata Therapeutics Limited (CYYNF)

Cynata Therapeutics Limited (OTCPK:CYYNF) Investor Webinar Conference Call February 5, 2025 6:30 PM ETCompany ParticipantsLauren Nowak - Media...

PR NewswireMELBOURNE, Australia, Dec. 4, 2024 MELBOURNE, Australia, Dec. 4, 2024 /PRNewswire/ -- Cynata Therapeutics Limited (ASX: "CYP", "Cynata", or the

CYP-006TK Demonstrates Safety and Efficacy in DFU Clinical Trial

The NSAIDs market is experiencing significant growth due to the rising incidence of chronic pain and inflammatory conditions such as arthritis and...

Further CYP-001 GvHD Clinical Data Published in Nature Medicine

Induced pluripotent stem cell (iPSC) market size from USD 2.1 billion in 2023 to USD 5.2 billion in 10 years. The growing incidence of cancer drive the...

Patient Enrolment Completed in CYP-006TK Diabetic Foot Ulcer Clinical Trial

Oct 08, 2020 / NTS GMTRoss Macdonald - Cynata Therapeutics Limited - CEO, MD Thanks, Tim, and welcome, everybody, to the session today. The development of stem

Global stem cell therapy market is segmented on the basis of therapy, and application. In terms of therapy, the market is segmented into autologous, and...

Visiongain has published a new report entitled Stem Cell Technologies and Applications Market Report 2023-2033: Forecasts by Type (Allogeneic Stem Cell...

Increase in the prevalence of chronic diseases, advances in stem cell research, and growth in investment in regenerative medicine are prominent factors...

Visiongain has published a new report entitled Stem Cell Technologies and Applications 2022-2032. It includes profiles of Stem Cell Technologies and...

Visiongain has published a new report entitled Stem Cell Technologies and Applications 2022-2032. It includes profiles of Stem Cell Technologies and...

/PRNewswire/ -- The